These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33681652)

  • 21. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
    Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
    Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
    Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
    Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
    [No Abstract]   [Full Text] [Related]  

  • 23. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy.
    Maguire M; Ben-Menachem E; Patten A; Malhotra M; Ngo LY
    Epilepsy Behav; 2022 Jan; 126():108483. PubMed ID: 34953337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis.
    Moseley BD; Dimova S; Elmoufti S; Laloyaux C; Asadi-Pooya AA
    Epilepsy Res; 2021 Oct; 176():106694. PubMed ID: 34218211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.
    Inoue Y; Tiamkao S; Zhou D; Cabral-Lim L; Lim KS; Lim SH; Tsai JJ; Moseley B; Wang L; Sun W; Hayakawa Y; Sasamoto H; Sano T; McClung C; Bass A
    Epilepsia Open; 2024 Jun; 9(3):1007-1020. PubMed ID: 38576178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perampanel as monotherapy or first adjunctive therapy in pediatric and adult patients with epilepsy: the first United States-based phase IV open-label ELEVATE study.
    Punia V; Klein P; Mihaylova T; Biton V; Samad O; Ngo LY; Kumar D; Malhotra M
    J Neurol; 2024 Jul; 271(7):4587-4598. PubMed ID: 38730096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.
    Trinka E; Tsong W; Toupin S; Patten A; Wilson K; Isojarvi J; James D
    Epilepsy Res; 2020 Oct; 166():106403. PubMed ID: 32673969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.
    French JA; Krauss GL; Biton V; Squillacote D; Yang H; Laurenza A; Kumar D; Rogawski MA
    Neurology; 2012 Aug; 79(6):589-96. PubMed ID: 22843280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of perampanel as early add-on therapy in Chinese patients with focal-onset seizures: a multicenter, open-label, single-arm study.
    Gao L; Lu Q; Wang Z; Yue W; Wang G; Shao X; Guo Y; Yi Y; Hong Z; Jiang Y; Xiao B; Cui G; Gao F; Hu J; Liang J; Zhang M; Wang Y
    Front Neurol; 2023; 14():1236046. PubMed ID: 37712083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
    Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
    Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety, and tolerability of adjunctive eslicarbazepine acetate in patients with focal to bilateral tonic-clonic seizures.
    Chung S; Guirguis S; Cantu D; Moreira J; Magalhães LM; Hall D; Grinnell T
    Epilepsy Res; 2024 Feb; 200():107285. PubMed ID: 38183687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life in pediatric patients with partial onset seizures or primary generalized tonic-clonic seizures receiving adjunctive perampanel.
    Trigg A; Brohan E; Cocks K; Jones A; Tahami Monfared AA; Chabot I; Meier G; Campbell R; Li H; Ngo LY
    Epilepsy Behav; 2021 May; 118():107938. PubMed ID: 33839450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of primary generalized tonic-clonic seizures.
    Kerr WT; Ngo LY; Zhu L; Patten A; Cheng JY; Reddy AS; French JA
    Epilepsia; 2024 Aug; 65(8):2412-2422. PubMed ID: 38864472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective, real-world experience of perampanel monotherapy in patient with first new onset focal seizure: A Thailand experience.
    Chinvarun Y
    Epilepsia Open; 2022 Mar; 7(1):67-74. PubMed ID: 34741590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.